Takeda booked a $2.5 billion provision tied to an antitrust pay-for-delay verdict after a Boston federal jury found the company liable in a class-action dispute involving Amitiza. The jury found Takeda faced liability for allegedly conspiring to delay generic entry, driving overpayments across pharmacies, health plans, insurers, and retailers. Takeda said it intends to pursue post-trial motions, seek an appeal, and ask for a stay. Still, the verdict forced Takeda to revise FY2025 earnings, swinging the company from net profit to a substantial reported loss. Takeda no longer sells Amitiza after the licensing relationship with Sucampo ended in 2024. The case centers on a settlement history that delayed generic availability until 2021, and the court’s damages framework could potentially triple amounts under U.S. antitrust law. The financial hit underscores how pay-for-delay litigation risk remains a live variable in pharma portfolio and contract strategy.